Vedolizumab for Crohn's disease

@article{Mosli2013VedolizumabFC,
  title={Vedolizumab for Crohn's disease},
  author={Mahmoud Hisham Mosli and Brian G. Feagan},
  journal={Expert Opinion on Biological Therapy},
  year={2013},
  volume={13},
  pages={455 - 463}
}
  • M. Mosli, B. Feagan
  • Published 11 February 2013
  • Medicine, Biology
  • Expert Opinion on Biological Therapy
Introduction: Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed. Areas covered: This review discusses the potential role of vedolizumab, a humanised monoclonal antibody… 
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
TLDR
Vedolizumab is an integrin antagonist which is thought to act by reducing inflammation by selectively inhibiting leukocyte migration in the gut, and a promising new agent for IBD patients refractory to anti-TNF therapy.
Vedolizumab in the treatment of Crohn’s disease
TLDR
Vedolizumab had a favorable safety profile and specifically showed no evidence of PML, reactivation of latent TB or hepatitis B, and can be given as a first-line therapy or following treatment failure, and was tolerated as part of combination therapy.
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
  • A. Armuzzi, P. Gionchetti, F. Rizzello
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2016
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.
TLDR
The limitation of current therapy as well as mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials are explored.
Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease
TLDR
Biologics targeting integrins show promise as therapeutics in the treatment of inflammatory bowel disease in patients who are either nonresponsive or intolerant to traditional approaches, though further research is necessary to optimize treatment efficacies.
Introducing vedolizumab to clinical practice: who, when, and how?
TLDR
The safety, tolerability, and efficacy profile of VDZ place it as a new therapy in IBD, though further trials directly comparing VDz with other biological agents as well as pragmatic studies to evaluate cost-effectiveness are necessary.
Recent insights into the molecular pathogenesis of Crohn’s disease: a review of emerging therapeutic targets
TLDR
Recent studies targeting intestinal immunology and its molecular activation pathways provide new possibilities for therapeutics, including antitumor necrosis factor molecules, which were a breakthrough in IBD, improving mucosal healing and resection-free survival rate and other classes of therapeutic agents come to focus.
Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
TLDR
Data from clinical trials of novel targeted therapies for psoriatic arthritis and other autoimmune diseases, which have produced sometimes surprising results, can inform the understanding of the immunopathogenesis of these diseases and help to identify the most relevant therapeutic targets.
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
TLDR
Vedolizumab was more effective than placebo as induction and maintenance therapy for IBDs, with an acceptable short-term safety profile, and achieving cure, although it may be associated with serious adverse events and nasopharyngitis for patients with CD.
Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities.
TLDR
Based on extensive research over the last decade, besides the conventional therapy, there are several novel pathways and specific targets, on which focus new therapeutics that aim to correct genetic susceptibility or restore the immune dysregulation.
...
...

References

SHOWING 1-10 OF 77 REFERENCES
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
TLDR
Vedolizumab is an integrin antagonist which is thought to act by reducing inflammation by selectively inhibiting leukocyte migration in the gut, and a promising new agent for IBD patients refractory to anti-TNF therapy.
Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.
TLDR
Emerging data suggest that earlier use of biological therapy is associated with improved clinical outcomes and potential disease-modifying effects and will likely lead to the expanded use of such agents in the treatment of Crohn's disease.
Medical management of Crohn's disease.
TLDR
It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD and may well become the preferred treatment objective.
Corticosteroids in Crohn’s disease
TLDR
Alternative classes of medical therapy for Crohn's disease, including modified corticosteroids and a group of new biological therapies, have proven to be efficacious in the management of active and/or quiescent Crohn't disease.
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.
TLDR
The limitation of current therapy as well as mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials are explored.
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
  • B. Feagan, G. Greenberg, A. Parikh
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2008
Evolving medical therapies for ulcerative colitis
  • R. Cohen
  • Medicine, Biology
    Current gastroenterology reports
  • 2001
TLDR
Control of ulcerative colitis may require an individualized approach for each patient, and biologic therapies targeting tumor necrosis factor, adhesion molecules, or other cytokines are under intense scrutiny as potential disease-altering agents that may even replace currently available products.
Evolving medical therapies for ulcerative colitis
TLDR
Patients with ulcerative colitis have traditionally relied on sulfasalazine, mesalamine, and corticosteroids as the mainstay of medical therapy, but the next generation of evolving therapies includes many novel agents that target various aspects of the human immune response.
Natalizumab for active Crohn's disease.
TLDR
Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease.
Methotrexate treatment for Crohn's disease.
  • B. Feagan
  • Medicine
    Inflammatory bowel diseases
  • 1998
TLDR
With the 1994 pediatric Final Rule, the establishment of the Pediatrics Committee at FDA, and the development of the pediatric pharmacology research units by the National Inqtitute of Child Health and Human Development, the PPRU Network is in a position to properly and expeditiously obtain critical pediatric data for both currently available and investigational drugs for the first time.
...
...